HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E

Redifferentiation therapy with BRAF/MEK inhibitors to facilitate treatment with radioiodine represents a good choice for radioiodine-refractory differentiated thyroid carcinoma, but recent initial clinical outcomes were modest. MAPK rebound caused by BRAF/MEK inhibitors-induced activation of HER2/HE...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Lingxiao, Jin, Yuchen, Liu, Min, Ruan, Maomei, Chen, Libo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386727/
https://www.ncbi.nlm.nih.gov/pubmed/28423638
http://dx.doi.org/10.18632/oncotarget.15773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386727/
https://www.ncbi.nlm.nih.gov/pubmed/28423638
http://dx.doi.org/10.18632/oncotarget.15773

Ejemplares similares